The phase-3 trials of Covaxin ensure unparalleled safety against the Covid-19 virus with:
- 93% efficacy against severe Covid-19 disease, reducing hospitalizations
- 78% efficacy against mild, moderate, and severe Covid-19 disease pic.twitter.com/GcAtP1SG29— Prasar Bharati News Services पी.बी.एन.एस. (@PBNS_India) July 3, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


